1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. May 2021;71(3):209-249. doi:10.3322/caac.21660
2. Nielsen S, Narayan AK. Breast Cancer Screening Modalities, Recommendations, and Novel Imaging Techniques. Surg Clin North Am. Feb 2023;103(1):63-82. doi:10.1016/j.suc.2022.08.004
3. Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers in breast cancer. Clin Exp Med. Jan 15 2022;doi:10.1007/s10238-021-00781-1
4. Kocaman N, Kuloglu T. Expression of asprosin in rat hepatic, renal, heart, gastric, testicular and brain tissues and its changes in a streptozotocin-induced diabetes mellitus model. Tissue Cell. Oct 2020;66:101397. doi:10.1016/j.tice.2020.101397
5. Kocaman N, Yuksel EI, Demir B, Calik I, Cicek D. Two Novel Biomarker Candidates for Differentiating Basal Cell Carcinoma from Trichoblastoma; Asprosin and Meteorine Like Peptide. Tissue Cell. Jun 2022;76:101752. doi:10.1016/j.tice.2022.101752
6. Wang M, Yin C, Wang L, et al. Serum Asprosin Concentrations Are Increased and Associated with Insulin Resistance in Children with Obesity. Ann Nutr Metab. 2019;75(4):205-212. doi:10.1159/000503808
7. Baserga R, Resnicoff M, Dews M. The IGF-I receptor and cancer. Endocrine. Aug 1997;7(1):99-102. doi:10.1007/BF02778073
8. Wang Y, Qu H, Xiong X, et al. Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion. Mediators Inflamm. 2018;2018:9471583. doi:10.1155/2018/9471583
9. Kim J, DeBerardinis RJ. Mechanisms and Implications of Metabolic Heterogeneity in Cancer. Cell Metab. Sep 3 2019;30(3):434-446. doi:10.1016/j.cmet.2019.08.013
10. Ohnuki K, Tohno E, Tsunoda H, Uematsu T, Nakajima Y. Overall assessment system of combined mammography and ultrasound for breast cancer screening in Japan. Breast Cancer. Mar 2021;28(2):254-262. doi:10.1007/s12282-020-01203-y
11. Gordon PB. The Impact of Dense Breasts on the Stage of Breast Cancer at Diagnosis: A Review and Options for Supplemental Screening. Curr Oncol. May 17 2022;29(5):3595-3636. doi:10.3390/curroncol29050291
12. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. Oct 20 2015;314(15):1599-614. doi:10.1001/jama.2015.12783
13. Ren W, Chen M, Qiao Y, Zhao F. Global guidelines for breast cancer screening: A systematic review. Breast. Aug 2022;64:85-99. doi:10.1016/j.breast.2022.04.003
14. Gui Y, Pan Q, Chen X, Xu S, Luo X, Chen L. The association between obesity related adipokines and risk of breast cancer: a meta-analysis. Oncotarget. Sep 26 2017;8(43):75389-75399. doi:10.18632/oncotarget.17853
15. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. Sep 2007;8(5):395-408. doi:10.1111/j.1467-789X.2007.00396.x
16. Akkus G, Koyuturk LC, Yilmaz M, Hancer S, Ozercan IH, Kuloglu T. Asprosin and meteorin-like protein immunoreactivity in invasive ductal breast carcinoma stages. Tissue Cell. Aug 2022;77:101855. doi:10.1016/j.tice.2022.101855
17. Kocaman N, Artas G. Can novel adipokines, asprosin and meteorin-like, be biomarkers for malignant mesothelioma? Biotech Histochem. Apr 2020;95(3):171-175. doi:10.1080/10520295.2019.1656344
18. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. Aug 30 2014;384(9945):755-65. doi:10.1016/S0140-6736(14)60892-8
19. Hwang AB, Lee SJ. Regulation of life span by mitochondrial respiration: the HIF-1 and ROS connection. Aging (Albany NY). Mar 2011;3(3):304-10. doi:10.18632/aging.100292
20. Zhang R, Yin X, Shi H, et al. Adiponectin modulates DCA-induced inflammation via the ROS/NF-kappa B signaling pathway in esophageal adenocarcinoma cells. Dig Dis Sci. Jan 2014;59(1):89-97. doi:10.1007/s10620-013-2877-5
21. Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol. Oct 2009;6(5):327-34. doi:10.1038/cmi.2009.43